CorMedix (NASDAQ: CRMD) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $30 thousand versus the consensus estimate of $3.5 thousand.

For earnings history and earnings-related data on CorMedix (CRMD) click here.